

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young et al.

Confirmation No.: 3135

Application No.: 10/657,363

Group Art Unit: 1648

Filed: September 8, 2003

Examiner: Hill, Myron G.

For: **ULTRA HIGH AFFINITY
NEUTRALIZING ANTIBODIES**

Attorney Docket No.: 10271-159-999
(*CAM: 209073-999157*)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. Copies of the listed documents are being submitted herewith to comply with the provisions of 37 C.F.R. §§1.97 and 1.98.

No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made. 37 C.F.R. §§1.97(g) and (h).

Applicants respectfully request that listed documents I01-I21 be considered by the Examiner and be made of record in the present application, and that an initialed copy of the enclosed List of References Cited by Applicant be returned in accordance with M.P.E.P. §609.

The listed documents are being submitted in compliance with 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b) but before the mailing date of any final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closed prosecution in the application.

U.S. Serial No. 10/657,363
Supplemental Information Disclosure Statement
December 19, 2008
Page 2 of 2

The fee is estimated to be \$180 for filing of this submission and will be paid via EFS web. Please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,



Tamera M. Weisser, Ph.D. (Reg. No. 47,856)

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, NY 10017-6702
(212) 326-3939

Enclosure